Skip to main content

Advertisement

SpringerLink
Log in

Effect of fosfomycin-induced hypernatremia on patients’ hospital stay length and survival

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background and objective

Hypernatremia is a possible side effect of intravenous fosfomycin. The aim of this study was to investigate the effects of changes in sodium (Na) levels on hospital stay and survival in patients hospitalized in the intensive care unit receiving fosfomycin.

Subjects and methods

This study was conducted retrospectively on the files of patients over the age of 60, who were admitted to the Internal Medicine Intensive Care Unit. Plasma sodium levels were observed and documented over a period of 14 days. The patients were divided into two groups (Hypernatremia group Na > 145 mEq/L vs normonatremia group 135–145 mEq/L). In addition, daily sodium changes were noted for 14 days in patients.

Results

The mean age of the patients was 75 years. Hospitalization days were longer for hypernatremia patients (31.5 days vs 41 days, p = 0.003). Patients with hypernatremia had an extended duration of stay in the intensive care unit. (21 days vs 31 days p = 0.002). The 1-month survival rate was 61.4% in patients with hypernatremia and 24.9% in patients without hypernatremia (p = 0.004). The absence of hypernatremia increases mortality by 2.09 times (95% CI 1.35–3.23). When discharge and mortality rates were analyzed according to sodium fluctuation, discharged patients exhibited a lower sodium fluctuation (4 min/max (−10/19) vs 6 min/max (−16/32) p < 0.001).

Conclusion

In conclusion, the strength of our study is that it specifically focuses on the consequences of the sodium fluctuation on patient management and provides results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Matthews PC, Barrett LK, Warren S et al (2016) Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infect Dis 16(1):556

    Article  PubMed  PubMed Central  Google Scholar 

  2. Hashemian SMR, Farhadi Z, Farhadi T (2019) Fosfomycin: the characteristics, activity, and use in critical care. Ther Clin Risk Manag 27(15):525–530

    Article  Google Scholar 

  3. Cao Y, Peng Q, Li S et al (2019) The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic. RSC Adv 9(72):42204–42218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Anastasia A, Bonura S, Rubino R et al (2023) The use of intravenous fosfomycin in clinical practice: a 5-year retrospective study in a tertiary hospital in Italy. Antibiotics (Basel) 12(6):971

    Article  CAS  PubMed  Google Scholar 

  5. Ruiz Ramos J, Salavert Lletí M (2019) Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens. Rev Esp Quimioter 32(Suppl 1):45–54

    PubMed  PubMed Central  Google Scholar 

  6. Sastry S, Doi Y (2016) Fosfomycin: resurgence of an old companion. J Infect Chemother 22(5):273–80

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Iarikov D, Wassel R, Farley J, Nambiar S (2015) Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database. Infect Dis Ther 4(4):433–458

    Article  PubMed  PubMed Central  Google Scholar 

  8. Scavone C, Mascolo A, Bernardi FF et al (2022) Hypernatremia during intravenous treatment with fosfomycin: a retrospective medical record review study and an analysis of spontaneous reports in the eudravigilance database. Front Pharmacol 29(13):844122

    Article  Google Scholar 

  9. Giske CG, Turnidge J, Cantón R, Kahlmeter G (2022) EUCAST Steering Committee. Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). J Clin Microbiol 60(3):e0027621

    Article  PubMed  Google Scholar 

  10. Tauseef A, Zafar M, Syed E et al (2021) Prognostic importance of deranged sodium level in critically ill patients: a systemic literature to review. J Family Med Prim Care 10(7):2477–2481

    Article  PubMed  PubMed Central  Google Scholar 

  11. Polderman KH, Schreuder WO, Strack van Schijndel RJ, Thijs LG (1999) Hypernatremia in the intensive care unit: an indicator of quality of care? Crit Care Med 27(6):1105–1108

    Article  CAS  PubMed  Google Scholar 

  12. Olsen MH, Møller M, Romano S et al (2020) Association between ICU-acquired hypernatremia and in-hospital mortality: data from the medical information mart for intensive care III and the electronic ICU collaborative research database. Crit Care Explor 2(12):e0304

    Article  PubMed  PubMed Central  Google Scholar 

  13. Yun G, Baek SH, Kim S (2023) Evaluation and management of hypernatremia in adults: clinical perspectives. Korean J Intern Med 38(3):290–302

    Article  CAS  PubMed  Google Scholar 

  14. Tsegka KG, Voulgaris GL, Kyriakidou M et al (2022) Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review. Expert Rev Anti Infect Ther 20(1):33–43

    Article  CAS  PubMed  Google Scholar 

  15. Chen T-T, Chang Y-F, Wu Y-C (2023) Clinical use of intravenous fosfomycin in critical care patients in Taiwan. Pathogens 12(6):841

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Putensen C, Ellger B, Sakka SG et al (2019) Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection 47(5):827–836

    Article  CAS  PubMed  Google Scholar 

  17. Grabein B, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB (2017) Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect 23:363–372

    Article  CAS  PubMed  Google Scholar 

  18. Pontikis K, Karaiskos I, Bastani S et al (2014) Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing gram-negative bacteria. Int J Antimicrob Agents 43:52–59

    Article  CAS  PubMed  Google Scholar 

  19. Lombardi G, Ferraro PM, Calvaruso, and others (2019) Sodium fluctuations and mortality in a general hospitalized population. Kidney Blood Press Res 44(4):604–614

    Article  CAS  PubMed  Google Scholar 

  20. Grim CC, Termorshuizen F, Bosman RJ and others (2021) Association between an increase in serum sodium and in-hospital mortality in critically ill patients. Crit Care Med 49(12):2070–2079

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ng ACC, Chow V, Yong ASC and others (2013) Fluctuation of serum sodium and its impact on short and long-term mortality following acute pulmonary embolism. PLoS ONE 8(4):e61966

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Eagles ME, Tso MK, Macdonald RL (2018) Significance of fluctuations in serum sodium levels following aneurysmal subarachnoid hemorrhage: an exploratory analysis. J Neurosurg 131(2):420–425

    Article  PubMed  Google Scholar 

  23. Marshall DC, Salciccioli JD, Goodson RJ and others (2017) The association between sodium fluctuations and mortality in surgical patients requiring intensive care. J Crit Care 40:63–68

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Intensive Care, Department of Internal Medicine, Konya City Hospital, University of Health Sciences, Akabe, Adana Çevre Yolu Cd. No:135/1, 42020 Karatay, Konya, Turkey

    Korhan Kollu

  2. Department of Internal Medicine, Konya City Hospital, University of Health Sciences, Konya, Turkey

    Arife Bas

  3. Department of Critical Care Medicine, Meram School of Medicine, Necmettin Erbakan University, Konya, Turkey

    Funda Gok

  4. Division of Geriatrics, Department of Internal Medicine, Konya City Hospital, University of Health Sciences, Konya, Turkey

    Muhammet Cemal Kizilarslanoglu

Authors
  1. Korhan Kollu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arife Bas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Funda Gok
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Muhammet Cemal Kizilarslanoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Korhan Kollu.

Ethics declarations

Conflict of interests

The authors declare no competing interests.

Ethics approval

The study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Medical Faculty of the KTO Karatay University (Date: 14.07.2023, Decision No: 2023/020).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kollu, K., Bas, A., Gok, F. et al. Effect of fosfomycin-induced hypernatremia on patients’ hospital stay length and survival. Ir J Med Sci (2024). https://doi.org/10.1007/s11845-024-03718-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11845-024-03718-1

Keywords

Search

Navigation